(Q80534848)
Statements
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms (English)
Galimberti S
Benedetti E
Pelosini M
Brizzi S
Ciabatti E
Fazzi R
Stelitano C
Quintana G
Di Raimondo F